Drug intelligence / Profile preview

Yimu Granules

Development stage: Unknown
Lead developer: Zhuzhou Qianjin Pharmaceutical
Administration: Oral

Overview

Yimu Granules (益母颗粒) is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Zhuzhou Qianjin Pharmaceutical. It is composed of several herbal ingredients, including *Leonurus japonicus* (Motherwort/Yimucao), *Angelica sinensis* (Dangqui), *Ligusticum chuanxiong* (Chuanxiong), and *Aucklandia lappa* (Muxiang). The formulation is approved in China as an over-the-counter (OTC) medicine indicated for promoting blood circulation, regulating menstruation, and relieving pain. It is primarily used to treat menstrual disorders, dysmenorrhea, and postpartum abdominal pain caused by Qi stagnation and blood stasis.

Brand names: Qianjin
Other names: Qianjin Yimu GranulesYimu GranuleYimu Keli益母颗粒

Beyond the preview

Go deeper on Yimu Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yimu Granules.

Explore the full profile